Sahar F. Bannoura

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Asfar Sohail Azmi · 12 shared papers, 2021–2026 · strength 1.99
   • Paper KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered? DOI 10.3389/fonc.2022.1013902↗
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
2. Husain Yar Khan · 11 shared papers, 2022–2026 · strength 1.85
   • Paper KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered? DOI 10.3389/fonc.2022.1013902↗
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
3. Amro Aboukameel · 10 shared papers, 2022–2026 · strength 1.59
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
4. Md. Hafiz Uddin · 10 shared papers, 2021–2026 · strength 1.56
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
5. Bassel F. El‐Rayes · 7 shared papers, 2021–2026 · strength 1.13
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
6. Boris Pasche · 5 shared papers, 2023–2026 · strength 0.88
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
7. Philip A. Philip · 5 shared papers, 2021–2025 · strength 0.80
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
   • Paper Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. DOI 10.1016/j.adro.2022.101122↗
8. Muhammad Wasif Saif · 4 shared papers, 2024–2026 · strength 0.72
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
9. Ramzi M. Mohammad · 4 shared papers, 2024–2026 · strength 0.72
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
   • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
10. Yiwei Li · 5 shared papers, 2022–2023 · strength 0.71
    • Paper Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. DOI 10.1016/j.adro.2022.101122↗
    • Paper Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. DOI 10.1002/ctm2.1513↗
    • Paper Connecting the Human Microbiome and Pancreatic Cancer. DOI 10.1007/s10555-022-10022-w↗
11. Eliza Wright Beal · 4 shared papers, 2023–2026 · strength 0.70
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
12. Anthony Frank Shields · 4 shared papers, 2022–2026 · strength 0.64
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
    • Paper Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. DOI 10.1002/ctm2.1513↗
13. Bin Bao · 3 shared papers, 2025–2026 · strength 0.55
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer DOI 10.64898/2025.12.06.692635↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
14. Steve H. Kim · 3 shared papers, 2022–2025 · strength 0.44
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
    • Paper Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. DOI 10.1002/ctm2.1513↗
    • Paper Molecular profiling of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in cellular and LSL-Kras G12D/+; Trp53… DOI 10.1101/2022.03.08.481108↗
15. Rachel E. Sexton · 3 shared papers, 2022 · strength 0.40
    • Paper Connecting the Human Microbiome and Pancreatic Cancer. DOI 10.1007/s10555-022-10022-w↗
    • Paper Correction to: Connecting the human microbiome and pancreatic cancer. DOI 10.1007/s10555-022-10037-3↗
    • Paper Molecular profiling of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in cellular and LSL-Kras G12D/+; Trp53… DOI 10.1101/2022.03.08.481108↗
16. P. A. Philip · 2 shared papers, 2025–2026 · strength 0.37
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
17. Azeddine Atfi · 2 shared papers, 2025–2026 · strength 0.37
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
18. Kay‐Uwe Wagner · 2 shared papers, 2023–2024 · strength 0.33
    • Paper RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. DOI 10.1016/j.canlet.2024.217275↗
    • Paper Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor… DOI 10.1101/2023.12.18.572102↗
19. Bayan A. Al-Share · 2 shared papers, 2022 · strength 0.27
    • Paper Connecting the Human Microbiome and Pancreatic Cancer. DOI 10.1007/s10555-022-10022-w↗
    • Paper Correction to: Connecting the human microbiome and pancreatic cancer. DOI 10.1007/s10555-022-10037-3↗
20. William Adrian Hall · 1 shared paper, 2023 · strength 0.17
    • Paper Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. DOI 10.1016/j.adro.2022.101122↗
21. Susan Tsai · 1 shared paper, 2023 · strength 0.17
    • Paper Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. DOI 10.1016/j.adro.2022.101122↗
22. Mandana Kamgar · 1 shared paper, 2023 · strength 0.17
    • Paper Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. DOI 10.1016/j.adro.2022.101122↗
23. Tanya Odisho · 1 shared paper, 2023 · strength 0.14
    • Paper Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. DOI 10.1002/ctm2.1513↗
24. Ibrahim Hanna Azar · 1 shared paper, 2023 · strength 0.14
    • Paper Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. DOI 10.1002/ctm2.1513↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.